Proteomic profiling and network biology of colorectal cancer liver metastasis

Bartolomé, Rubén A.; Casal, J. Ignacio

doi:10.1080/14789450.2023.2275681

Cited by 2 publications

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once metastatic cells have reached the target organs, they first adhere to the endothelium and then, after extravasation, they invade the parenchyma of the target organs, which are the liver and the lung in the case of CRC. Metastatic CRC cancer cells display an organotropic attitude, the liver and the lung being the most frequent target organs; this is not strictly related to target organ anatomy, blood flow or the total amount of circulating tumor cells spreading to the liver and the lung [6,7]. The lung elective pattern of CRC metatastic spread is not yet completely understood; however, in some clinical trials, the genomic characterization of metastatic sites with respect to primary tumors helps to improve the awareness regarding the association between genomic pattern alterations and metastatic behavior in attempting to classify the organotropic activity of a specific primary tumor [8].…”

Section: Biology and Physiopathology Of Crc Metastasesmentioning

confidence: 99%

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Cancers

View full text Add to dashboard Cite

Colorectal cancer is the third-most-diagnosed cancer in males and in females, representing 8% of estimated new cases, and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9–12% are eligible for local treatments with radical intent, including surgical resection, SBRT (stereotactic body radiation therapy) and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy.

show abstract

Section: Biology and Physiopathology Of Crc Metastasesmentioning

confidence: 99%

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Preprint

View full text Add to dashboard Cite

Colorectal cancer is the third most diagnosed cancer in males and in females, representing 8% of estimated new cases and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9 – 12% are eligible for local treatments with radical intent, including surgical resection, SBRT and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy.

show abstract

Proteomic profiling and network biology of colorectal cancer liver metastasis

Cited by 2 publications

References 117 publications

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Contact Info

Product

Resources

About